Cargando…
Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching
Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had dec...
Autores principales: | Damiani, Giovanni, Odorici, Giulia, Pacifico, Alessia, Morrone, Aldo, Conic, Rosalynn R. Z., Davidson, Tima, Watad, Abdulla, Pigatto, Paolo D. M., Colombo, Delia, Malagoli, Piergiorgio, Fiore, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780469/ https://www.ncbi.nlm.nih.gov/pubmed/35056153 http://dx.doi.org/10.3390/ph15010095 |
Ejemplares similares
-
Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study
por: Damiani, Giovanni, et al.
Publicado: (2019) -
The Impact of Intermittent Fasting (Ramadan Fasting) on Psoriatic Arthritis Disease Activity, Enthesitis, and Dactylitis: A Multicentre Study
por: Adawi, Mohammad, et al.
Publicado: (2019) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016) -
Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021) -
The Impact of Ramadan Fasting on the Reduction of PASI Score, in Moderate-To-Severe Psoriatic Patients: A Real-Life Multicenter Study
por: Damiani, Giovanni, et al.
Publicado: (2019)